• Users Online: 246
  • Print this page
  • Email this page
Year : 2015  |  Volume : 4  |  Issue : 2  |  Page : 5

Pharmacologic approaches against Advanced Glycation End Products (AGEs) in diabetic cardiovascular disease

1 Department of Cardiovascular Sciences, Rome University of Campus Bio Medico, Rome, Italy
2 Cardiac Surgery Centre Cardiologique du Nord de Saint-Denis, Paris, France
3 Department of Cardiothoracic Surgery, Golden Jubilee National Hospital, Clydebank, Glasgow, UK
4 Department of Biochemical Sciences, La Sapienza University of Rome, Rome, Italy

Correspondence Address:
Cristiano Spadaccio
Department of Cardiothoracic Surgery, Golden Jubilee National Hospital, Clydebank, Glasgow
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.5812/cardiovascmed.4(2)2015.26949

Rights and Permissions

Context: Advanced Glycation End-Products (AGEs) are signaling proteins associated to several vascular and neurological complications in diabetic and non-diabetic patients. AGEs proved to be a marker of negative outcome in both diabetes management and surgical procedures in these patients. The reported role of AGEs prompted the development of pharmacological inhibitors of their effects, giving rise to a number of both preclinical and clinical studies. Clinical trials with anti-AGEs drugs have been gradually developed and this review aimed to summarize most relevant reports. Evidence Acquisition: Evidence acquisition process was performed using PubMed and ClinicalTrials.gov with manually checked articles. Results: Pharmacological approaches in humans include aminoguanidine, pyridoxamine, benfotiamine, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, statin, ALT-711 (alagebrium) and thiazolidinediones. The most recent promising anti-AGEs agents are statins, alagebrium and thiazolidinediones. The role of AGEs in disease and new compounds interfering with their effects are currently under investigation in preclinical settings and these newer anti-AGEs drugs would undergo clinical evaluation in the next years. Compounds with anti-AGEs activity but still not available for clinical scenarios are ALT-946, OPB-9195, tenilsetam, LR-90, TM2002, sRAGE and PEDF. Conclusions: Despite most studies confirm the efficacy of these pharmacological approaches, other reports produced conflicting evidences; in almost any case, these drugs were well tolerated. At present, AGEs measurement has still not taken a precise role in clinical practice, but its relevance as a marker of disease has been widely shown; therefore, it is important for clinicians to understand the value of new cardiovascular risk factors. Findings from the current and future clinical trials may help in determining the role of AGEs and the benefits of anti-AGEs treatment in cardiovascular disease.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded374    
    Comments [Add]    
    Cited by others 20    

Recommend this journal